SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease
Tau pathology spreads throughout the brain during AD pathogenesis. The DRN is among the first regions to develop tau pathology during this process. SSRI use restores the metabolic activity of the DRN and reduces plasma p-tau181.
Authors
- Derya Sargin (ORCID: https://orcid.org/0000-0001-8018-4329)
- Shaista Jabeen (ORCID: https://orcid.org/0000-0002-1888-2836)
- Jonathan R. Epp (ORCID: https://orcid.org/0000-0002-7968-8973)
- Liisa A.M. Galea (ORCID: https://orcid.org/0000-0003-2874-9972)
- Dylan J. Terstege (ORCID: https://orcid.org/0000-0002-5903-0875)
Institutions
- Centre for Addiction and Mental Health (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- Alberta Children's Hospital (CA)
- Hotchkiss Brain Institute (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/alz.14579
- Citations
- 12
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 13.97
Funders
- U.S. Department of Defense
- Alzheimer's Disease Neuroimaging Initiative
- Fondation Brain Canada
- Alzheimer Society
- National Institutes of Health
- Alzheimer Society Research Program
- Alberta Children's Hospital Research Institute
- Natural Sciences and Engineering Research Council of Canada
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering